Females in Psychedelic Research: A Perspective for Advancing Research and Practice

Summary & key facts

This opinion paper says that changes in female hormones, mainly estradiol (E2) and progesterone (P4), are not being studied enough in current psychedelic research. The authors explain that these hormones affect brain chemistry, connectivity, mood, thinking, and behavior. They argue that menstrual phase tracking and hormonal tests in studies could lower noisy data and help women give more informed consent about how hormones might influence psychedelic experiences.

Key facts:

• The paper identifies estradiol (E2) and progesterone (P4) as the primary ovarian hormones that interact with brain systems involved in psychedelics.
• E2 and P4 are reported to modulate key neurotransmitter systems including serotonin (5-HT), dopamine, GABA, and glutamate.
• Fluctuations across the menstrual cycle can influence 5-HT2A receptor expression and brain functional connectivity, which the authors say could affect the subjective intensity and possible therapeutic effects of psychedelics.
• The authors state that hormone oscillations also influence mindset, and mindset is an important factor in safe and effective psychedelic use.
• The paper recommends incorporating menstrual phase tracking and hormonal assays in clinical trials and observational studies to reduce data variability, support individualized care, and improve informed consent.
• This article is an opinion paper calling for more research and better clinical protocols to understand the interplay between female hormones and psychedelic pharmacology.

Abstract

The influence of ovarian hormone fluctuations on neurochemistry, cognition, and psychological responses remains insufficiently examined in current psychedelic research and clinical protocols. Traditional practices and case studies underscore the importance of accounting for these factors in investigations of psychedelic effects. This opinion paper explores the critical intersections between female hormones and psychedelic experiences, informing improved research and practice. Estradiol (E2) and progesterone (P4), the primary ovarian hormones, modulate neurotransmitter systems central to psychedelic pharmacology, including serotonin (5-HT), dopamine, GABA, and glutamate. These hormonal interactions affect interhemispheric communication, synaptic plasticity, mood, cognition, and behavior. Fluctuations across the menstrual cycle influence 5-HT2A receptor expression and functional connectivity, potentially modulating both the subjective intensity and therapeutic efficacy of psychedelics. Additionally, oscillations in female hormones across the menstrual and life cycles affect mindset, a significant factor in safe and effective psychedelic use. These findings suggest that female hormonal variability may play a pivotal role in psychedelic experiences. Incorporating menstrual phase tracking and hormonal assays in both clinical trials and observational studies can reduce data variability, support individualized care, and improve informed consent practices. This would improve data integrity and ensure that women are fully informed about the potential influence of their hormonal state on their psychedelic experience, supporting truly informed consent. This paper emphasizes the need for an improved understanding of the complex interplay between female-specific biology and psychedelic pharmacodynamics to advance safe, ethical, and effective psychedelic research and therapies for women.

Topics

Chemical synthesis and alkaloids Diverse academic research themes Psychedelics and Drug Studies

Categories

Clinical Psychology Psychology Social Sciences

Tags

Art Engineering Engineering ethics Humanities Perspective (graphical) Practice research Psychology Sociology Visual arts